Brooklyn ImmunoTherapeutics Announces Board Changes
Provided By Globe Newswire
Last update: Jun 7, 2022
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022:
BlackRock Technology and Private Equity Term Trust
NYSE:BTX (2/21/2025, 8:04:35 PM)
After market: 7.64 -0.02 (-0.26%)7.66
-0.2 (-2.54%)
Find more stocks in the Stock Screener
